Integrated Filing — IndAS

General information about company
Scrip Code	000000
NSE Symbol	REMUS
MSEI Symbol	NOTLISTED
ISIN	INE0O5T01011
Name of company	REMUS PHARMACEUTICALS LIMITED
Type of company	SME
Class of security	Equity
Date of start of financial year	01-Apr-2024
Date of end of financial year	31-Mar-2025
Date of board meeting when results were approved	17-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	12-May-2025
Description of presentation currency	INR (in Actuals)
Reporting Type	Half Yearly
Reporting Quarter	Yearly
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited for the quarter ended	Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Audited
Segment Reporting	Single segment
Description of single segment	Pharmaceuticals
Start date and time of board meeting	17-May-2025   12:00:00
End date and time of board meeting	17-May-2025   16:00:00
Whether cash flow statement is applicable on company	Yes
Type of cash flow statement	Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion
Whether the company has any related party?	Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)?	No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?	Yes
Latest Date on which RPT policy is updated	2025-02-27
Indicate Company website link for updated RPT policy of the Company	https://remuspharma.com/policies/
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?	Yes
No. of times funds raised during the quarter	1
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	No
Not Applicable

Financial Results Ind-AS
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-Oct-2024	01-Apr-2024
B	Date of end of reporting period	31-Mar-2025	31-Mar-2025
C	Whether results are audited or unaudited	Audited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1	Income
	Revenue from operations	414900000	791600000
	Other income	9600000	29100000
	Total income	424500000	820700000
2	Expenses
(a)	Cost of materials consumed	0	0
(b)	Purchases of stock-in-trade	173800000	352700000
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-700000	-2300000
(d)	Employee benefit expense	52400000	91700000
(e)	Finance costs	2000000	3800000
(f)	Depreciation, depletion and amortisation expense	11600000	18700000
(f)	Other Expenses
1	Other Expenses	42000000	89700000
	Total other expenses	42000000	89700000
	Total expenses	281100000	554300000
3	Total profit before exceptional items and tax	143400000	266400000
4	Exceptional items	0	0
5	Total profit before tax	143400000	266400000
6	Tax expense
7	Current tax	35900000	66700000
8	Deferred tax	400000	700000
9	Total tax expenses	36300000	67400000
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
11	Net Profit Loss for the period from continuing operations	107100000	199000000
12	Profit (loss) from discontinued operations before tax	0	0
13	Tax expense of discontinued operations	0	0
14	Net profit (loss) from discontinued operation after tax	0	0
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
16	Total profit (loss) for period	107100000	199000000
17	Other comprehensive income net of taxes	700000000	700000000
18	Total Comprehensive Income for the period	807100000	899000000
19	Total profit or loss, attributable to
	Profit or loss, attributable to owners of parent
	Total profit or loss, attributable to non-controlling interests
20	Total Comprehensive income for the period attributable to
	Comprehensive income for the period attributable to owners of parent
	Total comprehensive income for the period attributable to owners of parent non-controlling interests
21	Details of equity share capital
	Paid-up equity share capital	58900000	58900000
	Face value of equity share capital	10	10
27	Details of debt securities
22	Reserves excluding revaluation reserve		2363300000
23	Earnings per share
i	Earnings per equity share for continuing operations
	Basic earnings (loss) per share from continuing operations	18.16	33.75
	Diluted earnings (loss) per share from continuing operations	18.16	33.75
ii	Earnings per equity share for discontinued operations
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
ii	Earnings per equity share
	Basic earnings (loss) per share from continuing and discontinued operations	18.16	33.75
	Diluted earnings (loss) per share from continuing and discontinued operations	18.16	33.75
24	Debt equity ratio
25	Debt service coverage ratio
26	Interest service coverage ratio
27	Disclosure of notes on financial results

Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio

Statement of Asset and Liabilities
Particulars		Year ended (dd-mm-yyyy)
Date of start of reporting period		01-Apr-2024
Date of end of reporting period		31-Mar-2025
Whether results are audited or unaudited		Audited
Nature of report standalone or consolidated		Standalone
	Assets
1	Non-current assets
	Property, plant and equipment	69900000
	Capital work-in-progress	0
	Investment property	0
	Goodwill	0
	Other intangible assets	200000
	Intangible assets under development	600000
	Biological assets other than bearer plants	0
	Investments accounted for using equity method	0
	Non-current financial assets
	Non-current investments	2088000000
	Trade receivables, non-current	0
	Loans, non-current	12000000
	Other non-current financial assets	93200000
	Total non-current financial assets	2193200000
	Deferred tax assets (net)	0
	Other non-current assets	100000
	Total non-current assets	2264000000
2	Current assets
	Inventories	21200000
	Current financial asset
	Current investments	0
	Trade receivables, current	156300000
	Cash and cash equivalents	34600000
	Bank balance other than cash and cash equivalents	9100000
	Loans, current	64600000
	Other current financial assets	192000000
	Total current financial assets	456600000
	Current tax assets (net)	0
	Other current assets	61300000
	Total current assets	539100000
3	Non-current assets classified as held for sale	0
4	Regulatory deferral account debit balances and related deferred tax Assets	0
	Total assets	2803100000
	Equity and liabilities
1	Equity
	Equity attributable to owners of parent
	Equity share capital	58900000
	Other equity	2363300000
	Total equity attributable to owners of parent	2422200000
	Non controlling interest
	Total equity	2422200000
2	Liabilities
	Non-current liabilities
	Non-current financial liabilities
	Borrowings, non-current	17800000
	Trade payables, non-current
	(A) Total outstanding dues of micro enterprises and small enterprises	0
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	0
	Total Trade payable	0
	Other non-current financial liabilities	16600000
	Total non-current financial liabilities	34400000
	Provisions, non-current	6700000
	Deferred tax liabilities (net)	229000000
	Deferred government grants, Non-current	0
	Other non-current liabilities	0
	Total non-current liabilities	270100000
	Current liabilities
	Current financial liabilities
	Borrowings, current	3600000
	Trade payables, current
	(A) Total outstanding dues of micro enterprises and small enterprises	18300000
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	32200000
	Total Trade payable	50500000
	Other current financial liabilities	7600000
	Total current financial liabilities	61700000
	Other current liabilities	46100000
	Provisions, current	3000000
	Current tax liabilities (Net)	0
	Deferred government grants, Current	0
	Total current liabilities	110800000
3	Liabilities directly associated with assets in disposal group classified as held for sale	0
4	Regulatory deferral account credit balances and related deferred tax liability	0
	Total liabilities	380900000
	Total equity and liabilites	2803100000
	Disclosure of notes on assets and liabilities

Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars		3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-Oct-2024	01-Apr-2024
Date of end of reporting period		31-Mar-2025	31-Mar-2025
Whether accounts are audited or unaudited		Audited	Audited
Nature of report standalone or consolidated		Standalone	Standalone
1	Segment Revenue (Income)
	(net sale/income from each segment should be disclosed)
	Total Segment Revenue
	Less: Inter segment revenue
	Revenue from operations
2	Segment Result
	Profit (+) / Loss (-) before tax and interest from each segment
	Total Profit before tax
	i. Finance cost
	ii. Other Unallocable Expenditure net off Unallocable income
	Profit before tax
3	(Segment Asset - Segment Liabilities)
	Segment Asset
	Total Segment Asset
	Un-allocable Assets	null	null
	Net Segment Asset	null	null
4	Segment Liabilities
	Segment Liabilities
	Total Segment Liabilities
	Un-allocable Liabilities	null	null
	Net Segment Liabilities	null	null
	Disclosure of notes on segments

Other Comprehensive Income
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-Oct-2024	01-Apr-2024
B	Date of end of reporting period	31-Mar-2025	31-Mar-2025
C	Whether results are audited or unaudited	Audited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone
	Other comprehensive income [Abstract]
1	Amount of items that will not be reclassified to profit and loss
1	Items that will be not reclassified t profit or loss	817400000	817400000
	Total Amount of items that will not be reclassified to profit and loss	817400000	817400000
2	Income tax relating to items that will not be reclassified to profit or loss	116900000	116900000
3	Amount of items that will be reclassified to profit and loss
1	Items that will be reclassified t profit or loss	-700000	-700000
	Total Amount of items that will be reclassified to profit and loss	-700000	-700000
4	Income tax relating to items that will be reclassified to profit or loss	-200000	-200000
5	Total Other comprehensive income	700000000	700000000

Cash flow statement, indirect
Particulars				Year ended (dd-mm-yyyy)
A	Date of start of reporting period			2024-04-01
B	Date of end of reporting period			2025-03-31
C	Whether results are audited or unaudited			Audited
D	Nature of report standalone or consolidated			Standalone
Part I	Blue color marked fields are non-mandatory.
	Statement of cash flows
	Cash flows from used in operating activities
	Profit before tax			266400000
	Adjustments for reconcile profit (loss)
	Adjustments for finance costs			3800000
	Adjustments for decrease (increase) in inventories			-2300000
	Adjustments for decrease (increase) in trade receivables, current			-10300000
	Adjustments for decrease (increase) in trade receivables, non-current			0
	Adjustments for decrease (increase) in other current assets			1400000
	Adjustments for decrease (increase) in other non-current assets			0
	Adjustments for other financial assets, non-current			0
	Adjustments for other financial assets, current			5100000
	Adjustments for other bank balances			300000
	Adjustments for increase (decrease) in trade payables, current			-31300000
	Adjustments for increase (decrease) in trade payables, non-current			0
	Adjustments for increase (decrease) in other current liabilities			-2500000
	Adjustments for increase (decrease) in other non-current liabilities			0
	Adjustments for depreciation and amortisation expense			18700000
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss			0
	Adjustments for provisions, current			3000000
	Adjustments for provisions, non-current			0
	Adjustments for other financial liabilities, current			800000
	Adjustments for other financial liabilities, non-current			0
	Adjustments for unrealised foreign exchange losses gains			0
	Adjustments for dividend income			0
	Adjustments for interest income			19900000
	Adjustments for share-based payments			0
	Adjustments for fair value losses (gains)			0
	Adjustments for undistributed profits of associates			0
	Other adjustments for which cash effects are investing or financing cash flow			0
	Other adjustments to reconcile profit (loss)			-2100000
	Other adjustments for non-cash items			0
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships			0
	Total adjustments for reconcile profit (loss)			-35300000
	Net cash flows from (used in) operations			231100000
	Dividends received			0
	Interest paid			0
	Interest received			0
	Income taxes paid (refund)			75200000
	Other inflows (outflows) of cash			0
	Net cash flows from (used in) operating activities			155900000
	Cash flows from used in investing activities
	Cash flows from losing control of subsidiaries or other businesses			0
	Cash flows used in obtaining control of subsidiaries or other businesses			0
	Other cash receipts from sales of equity or debt instruments of other entities			0
	Other cash payments to acquire equity or debt instruments of other entities			0
	Other cash receipts from sales of interests in joint ventures			0
	Other cash payments to acquire interests in joint ventures			0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships			0
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships			0
	Proceeds from sales of property, plant and equipment			3000000
	Purchase of property, plant and equipment			39500000
	Proceeds from sales of investment property			0
	Purchase of investment property			0
	Proceeds from sales of intangible assets			0
	Purchase of intangible assets			0
	Proceeds from sales of intangible assets under development			0
	Purchase of intangible assets under development			0
	Proceeds from sales of goodwill			0
	Purchase of goodwill			0
	Proceeds from biological assets other than bearer plants			0
	Purchase of biological assets other than bearer plants			0
	Proceeds from government grants			0
	Proceeds from sales of other long-term assets			0
	Purchase of other long-term assets			1200000
	Cash advances and loans made to other parties			35000000
	Cash receipts from repayment of advances and loans made to other parties			0
	Cash payments for future contracts, forward contracts, option contracts and swap contracts			0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts			0
	Dividends received			0
	Interest received			19900000
	Income taxes paid (refund)			0
	Other inflows (outflows) of cash			-71400000
	Net cash flows from (used in) investing activities	-124200000
	Cash flows from used in financing activities
	Proceeds from changes in ownership interests in subsidiaries			0
	Payments from changes in ownership interests in subsidiaries			0
	Proceeds from issuing shares			-400000
	Proceeds from issuing other equity instruments			0
	Payments to acquire or redeem entity's shares			0
	Payments of other equity instruments			0
	Proceeds from exercise of stock options			0
	Proceeds from issuing debentures notes bonds etc			0
	Proceeds from borrowings			7000000
	Repayments of borrowings			0
	Payments of lease liabilities			5200000
	Dividends paid			11800000
	Interest paid			3800000
	Income taxes paid (refund)			0
	Other inflows (outflows) of cash			0
	Net cash flows from (used in) financing activities			-14200000
	Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes			17500000
	Effect of exchange rate changes on cash and cash equivalents
	Effect of exchange rate changes on cash and cash equivalents			0
	Net increase (decrease) in cash and cash equivalents			17500000
	Cash and cash equivalents cash flow statement at beginning of period			17100000
	Cash and cash equivalents cash flow statement at end of period			34600000

Signatory Details
Name of signatory	Arpit Deepakkumar Shah
Designation of person	Managing Director
Place	Ahmedabad
Date	17-May-2025